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PTP1BPhosphotyrosine peptides are useful starting points for inhibitor design and for the search for protein tyr-
osine phosphatase (PTP) phosphoprotein substrates. To identify novel phosphopeptide substrates of
PTP1B, we developed a computational prediction protocol based on a virtual library of protein sequences
with known phosphotyrosine sites. To these we applied sequence-based methods, biologically meaning-
ful filters and molecular docking. Five peptides were selected for biochemical testing of their potential as
PTP1B substrates. All five peptides were equally good substrates for PTP1B compared to a known peptide
substrate whereas appropriate control peptides were not recognized, showing that our protocol can be
used to identify novel peptide substrates of PTP1B.
 2016 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
To date, the knowledge of phosphatase substrates is far less
than that of kinase substrates, and the identification of substrates
is one of the key challenges in phosphatase research.1 Peptides
can play a crucial role in finding new substrates.2 Furthermore,
they can be used as starting point for chemical tool development,
for example for inhibitors or pull-down baits.3 New peptide sub-
strates can be identified, for example, by using phosphopeptide
microarrays2,4 or peptide libraries.5 Computational methods are a
cheap alternative to the aforementioned approaches. They have
so far been applied to find protein substrates for phosphatases,6
and for analysis in combination with peptide microarrays.2 Here,
we have developed a computational protocol for identifying
human protein derived peptide substrates of protein-tyrosine
phosphatase 1B (PTP1B) as a model phosphatase. PTP1B is a
well-studied phosphatase involved in cancer and diabetes.7 Our
method led to the discovery of five biochemically confirmed novel
peptide substrates of PTP1B.
2. Results and discussion
As starting point we constructed a virtual library composed of
human proteins with known phosphotyrosine (pY) sites but not
containing artificial pY-containing sequences. Phospho.ELM,8PhosphoSitePlus9 and HPRD10 were used for this purpose. There
are in total 3799 non-redundant protein sequences in the library,
and 4931 non-redundant 11-mer peptides (with pY in the middle)
were extracted. The length of 11 amino acids was chosen following
previous studies testing PTP phosphopeptide substrate
specificity.4b,11
A sequence-based prediction that employs three methods
(Fig. 1) was then carried out on these sequences. These methods
are based on the dephosphorylation data from the human
DEPhOsphorylation Database DEPOD.1,12 While method 2 has been
used before for PTP1B substrate identification,2b the other two
methods have not, and they employ different algorithms than
method 2. We reasoned that the consensus prediction result
from all three methods would give us the best result for finding
PTP1B peptide substrates.
The 4931 extracted pY-containing peptides were assigned
information content-based scores (method 1) and also position
specific scoring matrix (PSSM) scores2b (method 2) and ranked
accordingly. The 3799 protein sequences, which contain 89874
tyrosines in total, were given to the pre-trained prediction
model customized for PTP1B in Musite.13 5825 tyrosines of the
89874 were predicted to be dephosphorylation sites for PTP1B
(specificityP 95%) (method 3). The top 10% peptides were taken
from each method. The three predictions were combined together
to get a common set, which are 139 non-redundant pY-containing
peptides. They correspond to 231 pY sites on 191 original protein
sequences (122 genes). Among them 15 genes code known pro-
tein substrates of PTP1B, and for 12 of them our predicted
Figure 1. Schematic flow-chart of the sequence-based prediction of dephosphorylation sites of PTP1B.
Figure 2. Superimposed complex structures between PTP1B and peptide sub-
strates: PTP1B from 1EEO19 is shown as cartoon, the residues surrounding the active
site are shown as sticks and peptide substrates are shown as lines. The carbon
atoms are colored with following scheme: 1EEN (green), 1EEO (cyan), 1G1F
(magenta), 1G1G (yellow), 1G1H (pink), 1PTT (gray), 1PTU (blue). (A) The residues
surrounding the active site of PTP1B show a different extent of flexibility in
complex with different peptide ligands; (B) The N–C terminal orientation of
peptides and three common hydrogen bonds formed between peptides and PTP1B—
H-bonds 1 and 2 between the Asp-48 carboxylate side chain and the main chain
nitrogens of the pY and residue 1 on peptides, H-bond 3 between the main chain
nitrogen of Arg-47 and the main chain carbonyl of residue-2 on peptides.
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tary Table S1). For the remaining 3 protein substrates dephospho-
rylation sites are unknown. DEPOD contains 39 substrates, and
we did not identify 24 of those. Reasons for this lie in the strict
cut-off that we applied to obtain the consensus results from the
three methods of the sequence-based prediction. For example,
the PTP1B substrate Src14 was predicted as good substrate only
by method 3 (Musite cut-off 95%, sequence score for STEPQpYQP-
GEN 98.48%), but not by methods 1 (rank 803/4931) and 2 (rank
985/4931). Since a strict cut-off generally decreases the chances
of finding false positives and since we did identify dephosphory-
lation sites of 13 proteins as well as 107 novel substrate candi-
dates, we judged the result of our cut-off setting as acceptable.
Next, we applied biologically meaningful filters which are
derived from DEPOD to the predicted substrates. The candidate
proteins should be either the known substrates of certain PTPs that
share common known substrates with PTP1B, or they should be
mapped within the same KEGG15 and NCI-Nature PID16 pathways
as PTP1B. The filtering resulted in 44 candidate protein substrates
including the 15 known protein substrates of PTP1B.
In order to refine the prediction result, of the predicted 29 novel
substrates of PTP1B 35 non-redundant 11-mer peptides with single
pY sites and 7 with double pY sites were extracted from original
protein sequences and converted to 3D chemical structures. Then
these peptide structures were docked into the PTP1B catalytic site
by GOLD17 and the docking solutions were further refined by
FlexPepDock in Rosetta.18 After that, the top docking solutions
were manually investigated to check if they satisfy the following
criteria: (i) the phosphotyrosine points into the catalytic site; (ii)
the N-C terminal orientation accords with reported ones; (iii) for-
mation of at least two of the three key hydrogen bonds19 (Fig. 2).
After this procedure, the docking solutions of 8 peptides were
found to satisfy these criteria (see Table 1, peptides 1–5, plus
two peptides from JAK1 and one from Fyn listed in the
Supplementary Table S1).
To test if the predicted phosphopeptides would indeed be
in vitro substrates of PTP1B, we synthesized six of these peptides.
The two peptides from JAK1 were not synthesized and tested
because the sequences are highly similar to the ones of the known
substrates JAK220 and MET21 that were also detected by our
procedure. Kinetic analysis of the corresponding JAK2 sequence
KEpYpYKVK yielded similar values as obtained for the peptides
tested here (Km = 12.7 lM; kcat/Km = 23.2  105 M1 s1),22 show-
ing that these type of peptide sequences are dephosphorylated byPTP1B in vitro. With the exception of the Fyn peptide, which
showed poor solubility, we then tested the enzymatic activity of
Table 1
Synthesized peptides and their activities as substrate of PTP1B
ID Source (gene
name)
pY
site
Sequence Km [lM] kcat/Km
(105 M1 s1)
1 ARHGAP5 1090 DPSDNpYAEPID 28.5 ± 5.0 11.6 ± 3.4
2 SKAP1 271 EEEDIpYEVLPD 14.7 ± 3.2 27.9 ± 13.9
3 GAB2 293 DNEDVpYTFKTP 17.1 ± 4.1 9.2 ± 1.6
4 ACP1 133 IEDPpYpYGNDSD 20.1 ± 4.6 8.9 ± 1.1
5 ITGB1 783 QENPIpYKSPIN 21.7 ± 8.9 7.1 ± 3.0
6 Src 530 STEPQpYQPGEN 29.1 ± 5.3 9.0 ± 3.7
7 — — KKKKpYPKK Inactive Inactive
8 NOS3 657 LGSRApYPHFCA >300 n.d.
n.d. = not determined. Peptides are acetylated at the N-terminus and contain an
amide at the C-terminus.
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phosphate assay23 (Table 1). We also synthesized and tested a pos-
itive control peptide from Src as known substrate of PTP1B,3,14 and
a negative control peptide which PTP1B does not dephosphory-
late.5e We found that the five peptides from the prediction were
equally good substrates for PTP1B as the Src peptide, whereas as
expected the negative control was not recognized. We also tested
a peptide from our prediction (peptide 8 in Table 1), which was
assigned low scores by all the three sequence-based methods,
and found that PTP1B recognized it poorly. These results
demonstrate that our protocol can successfully identify novel
peptide substrates of PTP1B, and that it can differentiate between
good and poor peptide substrates.
3. Conclusion
The here described computational approach lead to the discov-
ery of five novel phosphopeptide substrates for PTP1B. These sub-
strates can serve to develop substrate-based PTP1B inhibitors and
other peptide-based tools.3 In this case the step of applying
biologically meaningful filters could potentially be skipped. The
here-identified new peptide substrates are derived from known
phosphorylation sites on human proteins and biologically mean-
ingful filters were applied in the procedure. Through this proce-
dure we found 15 known protein substrates of PTP1B. Together,
this suggests that the peptides can be used to search for potential
physiological substrates of PTP1B. However, since we also detected
JAK1, which is not a natural substrate of PTP1B, the candidates
must be carefully studied in order to establish if they are natural
substrates. The example of Src, which was not identified by our
procedure, shows that our procedure is not exclusive; meaning
that among the hits listed in Supplementary Table S1 potentially
other substrate candidates can be found. Furthermore, we identi-
fied correct dephosphorylation sites for 12 of 15 protein substrates,
and for the remaining 3 proteins the dephosphorylation sites are
unknown, suggesting that the dephosphorylation sites on these
proteins could be predicted by the phosphopeptides that we iden-
tified by our method. In addition, we expect that our protocol can
be applied to other protein tyrosine phosphatases with known sub-
strate dephosphorylation sites and protein structure data as a
cheap alternative to peptide libraries and microarrays. Finally,
our approach should also be applicable to other enzymatic post-
translational protein modifications (PTMs) if there is (1) available
known PTM site information (sequence and position) and adequate
data to construct the positive and negative data set used for the
sequence-based prediction model; (2) applicable biological mean-
ingful filters such as enzyme substrate scope or pathway involve-
ment; and (3) available experimental structures or reliable
structure models of enzymes or enzyme-substrate complexes for
the molecular docking study.4. Experimental section
4.1. Computational methods
For the method 1 with information content-based score, the
sequence logo was produced from the multiple alignment of the
known dephosphorylation sites of PTP1B (5 amino acids before
and after the pY site) via WebLogo.24,25 Then scores were assigned
to query pY-containing peptides via adding up the height value of
amino acid i at the jth position (5 to 1 and 1 to 5) in the
sequence logo.
For the PSSM score method, three amino acid frequency matri-
ces (21 rows and 10 columns each) were generated: (i) the positive
matrix value at row i and column j is the frequency of amino acid i
(including blank where applicable) at the jth position (5 to 1
and 1 to 5) in the multiple alignment of the known dephosphory-
lation sites of PTP1B (11-mer with 5 amino acids before and after
the pY site); (ii) an analogous negative matrix which is based on
the alignment of all the tyrosine sites (11-mer) from human pro-
teins without any pY site annotation; (iii) a total matrix which is
based on the alignment of all the 11-mer peptides in positive
and negative matrices. Then the PSSM scores were assigned to
query pY-containing peptides by adding up the overall peptide
positions according to the formula in Figure 1.
Musite, which is a stand-alone application for phosphorylation
site prediction, was adapted to predict dephosphorylation sites via
customized prediction model training. We combined the protein
sequences containing known dephosphorylation sites of PTP1B
and human proteins without any pY site annotation together as
input to train the prediction model. The positive and negative
training sets are known dephosphorylation sites and the remaining
tyrosine sites, respectively. A query protein sequence is given to
this prediction model and the possible dephosphorylation sites
on the protein are predicted.
For molecular docking procedure the PTP1B structure was taken
from PDB entry 1EEO.19 200 docking solutions were generated for
each peptide by GOLD. During the docking process, the following
residues in catalytic site were treated as flexible: Gln-21, Arg-24,
Lys-41, Arg-47, Asp-48, Ser-118, Lys-120, Asp-181, and Phe-182.
The top 10 docking solutions were sent to FlexPepDock for further
refinement and 10  200 docking solutions were generated for
each peptide.
4.2. Peptide synthesis
All chemicals were obtained from Sigma–Aldrich (Steinheim,
Germany) and VWR (Darmstadt, Germany) and used without fur-
ther purification. Fmoc-protected amino acids and Rink amide AM
resin (200–400 mesh, 0.7 mmol/g) were purchased from
Novabiochem (Darmstadt, Germany). The following Fmoc protected
L-amino acids were used: Fmoc-Asn(Trt)-OH, Fmoc-Gln(Trt)-OH,
Fmoc-Glu(tBu)-OH, Fmoc-Gly-OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-
OH, Fmoc-Pro-OH, Fmoc-Tyr(PO(OBzl)OH)-OH, Fmoc-Ala-OH,
Fmoc-Phe-OH, Fmoc-Ile-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Ser(tBu)-
OH, Fmoc-Thr(tBu)-OH, Fmoc-Val-OH, Fmoc-His(Trt)-OH, Fmoc-
Cys(Trt)-OH and Fmoc-Asp(tBu)-OH. 2-(1H-Benzotriazole-1-yl)-
1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) and
Triisopropylsilane (TIS) were also purchased from Novabiochem.
HPLC–MS analysis and HPLC purifications were carried out on a
Shimadzu High Performance Liquid Chromatograph/Mass
Spectrometer LCMS-2010EV with an UV/Vis Photodiode array
detector SPD-M20A Prominence. The solvent mixtures were H2O
andMeCNwith 0.05% TFA added. RP-HPLC analytical runs were car-
ried out with a Macherey Nagel C18 EC 250/4.0 NUCLEODUR 100-5
C18 ec column and a pump rate of 1.5 ml/min. For semi-preparative
Table 2
Analytical data of the synthesized peptides
Peptide Calculated MW Observed MW HPLC gradient (% MeCN
in H2O incl. 0.05% TFA)
Retention time (min)
1 1355 1378.0 [M+Na]+ 10? 50 9.8
2 1470 1493.0 [M+Na]+ 10? 50 13.6
3 1448 1449.0 [M+H]+ 10? 50 11.2
4 1485 1509.9 [M+Na]+ 10? 50 8.5
5 1422 1423.2 [M+H]+ 10? 50 10.5
6 1369 1392.9 [M+Na]+ 10? 50 3.0
7 1296 1296.3 [M+H]+ 10? 50 1.8
8 1341 1342.1 [M+H]+ 10? 50 8.8
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C18 ec column and a pump rate of 5 ml/min was used. Mass spectra
were recorded on a MALDI micro MX mass spectrometer (Waters,
Manchester, UK) equipped with a reflectron analyzer, used in posi-
tive ion mode with delayed extraction activated.
Solid-phase peptide synthesis (SPPS) was performed as
described before3b with standard Fmoc chemistry on Rink amide
resin using an automated peptide synthesizer (Syro I,
Multisyntech). Acetylation, cleavage and ether-precipitation were
carried out as described before3b and the peptides were purified
by HPLC. Analytical data is presented in Table 2.
4.3. Protein expression and purification
PTP1B was expressed and purified as described previously.3
4.4. Phosphatase assay
The in vitro EnzChek phosphate assay was carried out with the
commercial kit from Molecular Probes as described previously.23
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